Home › Research › Health systems and care delivery
Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer's Disease in Italy: A scenario analysis
Giorelli Maurizio, Fazio Pasquale Di, Dimatteo Tiziana. JAR life, 2026-06-17
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Anti-amyloid monoclonal antibodies (lecanemab and donanemab) represent the first disease-modifying therapies for early symptomatic Alzheimer's disease (AD)- Italy's National Health Service (SSN) must determine whether to include these therapies within Essential Levels of Care (LEA), requiring reimbursement across all regions. To conduct a three-year budget impact analysis and implementation feasibility assessment for anti-amyloid therapies in Italy. The analysis was scenario-based rather than empirical. Deterministic budget modeling, combined with Proctor's 8-Domain Implementation Outcomes Framework and the Consolidated Framework for Implementation Research (CFIR), was employed. Four implementation scenarios were modeled based on cumulative patient uptake rates. Cost analysis incorporated diagnostic pathways, drug acquisition, clinical surveillance, and management of amyloid-related imaging abnormalities (ARIA). Infrastructure capacity was assessed through national survey data of Centers for Cognitive Disorders and Dementia (CCDDs). An estimated 42,000 patients in Italy are potentially eligible for anti-amyloid therapy. The moderate scenario (5-10-15% uptake over three years, reaching 14,100 cumulative patients) represents the optimal policy target, with estimated three-year total costs of €557.3 million (0.4% of the annual SSN budget), penetration of 33.6% of eligible patients, and a feasibility score of 1.5, underscoring a high implementation success probability. The moderate scenario remains financially sustainable but requires targeted infrastructure investment in the Central and Southern regions. Anti-amyloid therapy implementation is feasible within Italian healthcare system constraints under a moderate uptake scenario. However, achievement of equitable access requires substantial capacity building in underserved regions, clarified reimbursement policies, integrated diagnostic networks, and robust workforce planning before full LEA inclusion is recommended.
What this study adds
Evidence grade: Low
The record lists 42,000 participants. It is a budget and feasibility modelling exercise, not evidence that these therapies cure or prevent Alzheimer's disease. Reported effect size: 0.4%; 33.6%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Maurizio, G., Di, F. P., & Tiziana, D. (2026). Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer's Disease in Italy: A scenario analysis. JAR life. https://doi.org/10.1016/j.jarlif.2026.100076
Vancouver
Maurizio G, Di FP, Tiziana D. Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer's Disease in Italy: A scenario analysis. JAR life. 2026. doi:10.1016/j.jarlif.2026.100076. PMID: 42306480.
BibTeX
@article{maurizio2026-42306480,
author = {Maurizio, Giorelli and Di, Fazio Pasquale and Tiziana, Dimatteo},
title = {{Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer's Disease in Italy: A scenario analysis}},
journal = {JAR life},
year = {2026},
doi = {10.1016/j.jarlif.2026.100076},
pmid = {42306480},
url = {https://doi.org/10.1016/j.jarlif.2026.100076}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- An estimated 42,000 patients in Italy are potentially eligible for anti-amyloid therapy.
- The moderate scenario (5-10-15% uptake over three years, reaching 14,100 cumulative patients) represents the optimal policy target, with estimated three-year total costs of €557.3 million (0.4% of the annual SSN budget), penetration of 33.6% of eligible patients, and a feasibility score of 1.5, underscoring a high implementation success probability.
- The moderate scenario remains financially sustainable but requires targeted infrastructure investment in the Central and Southern regions.
- Anti-amyloid therapy implementation is feasible within Italian healthcare system constraints under a moderate uptake scenario.
- However, achievement of equitable access requires substantial capacity building in underserved regions, clarified reimbursement policies, integrated diagnostic networks, and robust workforce planning before full LEA inclusion is recommended.
Why it matters
This scenario analysis estimated that about 42,000 patients in Italy could be eligible for anti-amyloid monoclonal antibodies, and that a moderate uptake scenario reaching 14,100 patients over three years would cost €557.3 million, about 0.4% of the annual national health service budget. It is a budget and feasibility modelling exercise, not evidence that these therapies cure or prevent Alzheimer's disease.
Study details
- Participants42,000
- Effect size0.4%; 33.6%
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record, senior author's track record and institution's track record, so those were left out: it earned 34 of the 89 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (JAR life) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 42,000 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-17) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Tiziana Dimatteo holds only 8 work(s), too few to judge a track record — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42306480) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 34 / 89 | Scored on 17 of 20 parts. We have no data for the rest, so they are left out: 34 of the 89 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.